Craif
Craif is a venture company founded in 2018 originating from Nagoya University, specializing in high-precision detection of disease-related bio-substances such as microRNA from easily collectible body fluids like urine. The company is committed to early detection of cancer and personalized medicine using its proprietary platform, NanoIP™. Craif aims to develop innovative diagnostic tests to improve early cancer detection and tailored healthcare.
Industries
Nr. of Employees
small (1-50)
Products
Urine-based non-invasive cancer risk test (home and clinical kit)
A diagnostic offering that uses urine sampling, NGS-based microRNA profiling, and machine learning models to estimate risk for multiple cancer types. Available both as a home (remote) collection kit and via partner medical institutions.
Urine-based non-invasive cancer risk test (home and clinical kit)
A diagnostic offering that uses urine sampling, NGS-based microRNA profiling, and machine learning models to estimate risk for multiple cancer types. Available both as a home (remote) collection kit and via partner medical institutions.
Services
Clinical and translational research partnerships
Design and execution of joint clinical research projects with university hospitals and medical centers for assay evaluation and validation.
Assay development and biomarker discovery services
R&D services to develop urine-based molecular assays (microRNA, cfDNA, EV) and to identify disease-associated biomarker signatures.
Digital patient portal and remote testing operations
Provision and operation of a web-based portal for ordering tests, tracking sample progress, delivering electronic reports, and handling payments.
Clinical and translational research partnerships
Design and execution of joint clinical research projects with university hospitals and medical centers for assay evaluation and validation.
Assay development and biomarker discovery services
R&D services to develop urine-based molecular assays (microRNA, cfDNA, EV) and to identify disease-associated biomarker signatures.
Digital patient portal and remote testing operations
Provision and operation of a web-based portal for ordering tests, tracking sample progress, delivering electronic reports, and handling payments.
Expertise Areas
- Urine-based liquid biopsy and non-invasive diagnostics
- Biomarker discovery for cancer (microRNA, cfDNA, extracellular vesicles)
- Nanomaterials for biomolecule capture
- NGS-based molecular profiling
Key Technologies
- Urine microRNA sequencing (NGS)
- Nanowire-based extracellular vesicle capture
- cfDNA capture-and-release chemistry
- Proteomics for EV membrane proteins (mass spectrometry)